
    
      This is an open-label multi-center, multi-national rollover protocol to allow continued
      access to tivozanib for subjects who have participated in other tivozanib (monotherapy or
      combination) protocols, who are tolerating study drug, and displaying clinical benefit.

      Enrollment to this protocol will remain open to subjects who participate in current and
      future protocols with tivozanib. The end of the study is the last treatment visit of the last
      subject at the last site. Enrollment in this protocol will continue until tivozanib becomes
      commercially available in the country where the subject is being treated. If a subject is
      experiencing clinical benefit from tivozanib when the study is discontinued, the sponsor will
      make every effort to assist the subject in obtaining commercially available tivozanib.

      This rollover protocol will be open to eligible subjects on current and future protocols with
      tivozanib. The number of subjects who will enroll is dependent upon the number of subjects
      enrolled in tivozanib protocols that tolerate the drug, display clinical benefits, and are
      willing to participate.
    
  